Metabolic Responses to Metformin in Inoperable Early-stage Non–Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. (April 2020)

• Record Type: Journal Article
• Authors: Chun, Stephen G.; Liao, Zhongxing; Jeter, Melenda D.; Chang, Joe Y.; Lin, Steven H.; Komaki, Ritsuko U.; Guerrero, Thomas M.; Mayo, Ray C.; Korah, Bobby M.; Koshy, Suja M.; Heymach, John V.; Koong, Albert C.; Skinner, Heath D.
• Is Part Of: American journal of clinical oncology. Volume 43:Number 4(2020)
• Publication Date: 2020-04
• Subjects: SBRT -- NSCLC -- metformin -- PET scan; Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0000000000000632
• Languages: English
• ISSNs: 0277-3732

Abstract

Abstract : Background: Metformin reduces glucose uptake in physiologic tissues and has been shown to affect non–small cell lung cancer (NSCLC) metabolism. We hypothesized that positron emission tomography (PET) scans could detect the impact of metformin on glucose uptake in NSCLC and we sought to test this hypothesis in a prospective clinical trial. Materials and Methods: A single-blinded phase II clinical trial was performed with subjects randomized 6:1 to 3 to 4 weeks of metformin versus placebo for inoperable early-stage NSCLC. PET scans were performed at baseline, mid-treatment (after 2 wk study medication), and 6 months postradiation. The primary endpoint of the trial was tumor metabolic response to metformin by PERCIST before definitive radiation. Stereotactic body radiotherapy to 50 Gy in 4 fractions was used for peripheral tumors and 70 Gy in 10 fractions for central tumors. Results: There were 14 subjects randomized to the metformin and 1 to placebo. Histologies were 60% adenocarcinoma, 33.3% squamous cell carcinoma, and 6.7% poorly differentiated carcinoma. At mid-treatment PET scan, 57% of subjects randomized to metformin met PERCIST criteria for metabolic response, of which 75% had progressive metabolic disease and 25% had partial metabolic response, whereas the placebo subject had stable metabolic disease. At 6 months, the metformin arm had 69% complete metabolic response, 23% partial metabolic response and 1 progressive metabolic disease, and the subject treated with placebo had a complete metabolic response. There were no CTCAE grade ≥3 toxicities. Conclusions: Despite low accrual, majority of subjects treated with metformin had metabolic responses by PERCIST criteria on PET imaging. Contrary to the effect of metformin on most physiologic tissues, most tumors had increased metabolic activity in response to metformin.